PM
Prosight Management Portfolio holdings
AUM
$410M
This Quarter Return
-1.43%
1 Year Return
-14.96%
3 Year Return
+21.81%
5 Year Return
+1.17%
10 Year Return
–
AUM
$203M
AUM Growth
+$203M
(+0.6%)
Cap. Flow
-$7.15M
Cap. Flow
% of AUM
-3.53%
Top 10 Holdings %
Top 10 Hldgs %
50.42%
Holding
59
New
11
Increased
16
Reduced
17
Closed
14
Top Buys
| 1 |
Aurinia Pharmaceuticals
AUPH
|
$7.41M |
| 2 |
Baxter International
BAX
|
$6.39M |
| 3 |
Cue Biopharma
CUE
|
$6.01M |
| 4 |
Prothena Corp
PRTA
|
$5.45M |
| 5 |
MTCR
Metacrine, Inc. Common Stock
MTCR
|
$5.3M |
Top Sells
| 1 |
Kura Oncology
KURA
|
$17.7M |
| 2 |
Arrowhead Research
ARWR
|
$4.93M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$4.8M |
| 4 |
Aldeyra Therapeutics
ALDX
|
$3.91M |
| 5 |
Iovance Biotherapeutics
IOVA
|
$3.11M |
Sector Composition
| 1 | Healthcare | 92.16% |
| 2 | Technology | 4.47% |
| 3 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $13.3M | 6.3% | 115,800 +25,800 | +29% | +$2.95M |
|
|
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $12.2M | 5.8% | 163,057 -64,155 | -28% | -$4.8M |
|
3
Bristol-Myers Squibb
BMY
$96B
| $11.2M | 5.32% | 185,500 +67,500 | +57% | +$4.07M |
|
|
RETA
4
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $11.2M | 5.31% | 114,554 +32,454 | +40% | +$3.16M |
|
|
5
Cue Biopharma
CUE
$60M
| $10.7M | 5.08% | 709,936 +399,642 | +129% | +$6.01M |
|
|
6
Baxter International
BAX
$12.7B
| $9.81M | 4.67% | 122,000 +79,500 | +187% | +$6.39M |
|
|
CHNG
7
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $9.06M | 4.31% | 624,200 -205,900 | -25% | -$2.99M |
|
|
8
Aurinia Pharmaceuticals
AUPH
$1.58B
| $8.76M | 4.17% | 595,000 +503,000 | +547% | +$7.41M |
|
|
9
Aldeyra Therapeutics
ALDX
$351M
| $8.09M | 3.85% | 1,092,000 -528,200 | -33% | -$3.91M |
|
10
Cigna
CI
$80.3B
| $7.96M | 3.79% | 47,000 +8,500 | +22% | +$1.44M |
|
11
Encompass Health
EHC
$12.3B
| $7.01M | 3.34% | 107,921 +75,021 | +228% | +$4.88M |
|
12
Centene
CNC
$14.3B
| $6.88M | 3.27% | 117,935 -41,765 | -26% | -$2.44M |
|
|
APTO
13
DELISTED
Aptose Biosciences, Inc.
APTO
| $6.84M | 3.25% | 1,139,094 +356,021 | +45% | +$2.14M |
|
14
Zimmer Biomet
ZBH
$21B
| $6.62M | 3.15% | 48,600 -19,900 | -29% | -$2.71M |
|
15
uniQure
QURE
$896M
| $6.31M | 3% | 171,429 +28,300 | +20% | +$1.04M |
|
|
16
Prothena Corp
PRTA
$441M
| $5.45M | 2.59% | +545,195 | New | +$5.45M |
|
|
MTCR
17
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $5.3M | 2.52% | +518,796 | New | +$5.3M |
|
18
MeiraGTx Holdings
MGTX
$587M
| $5.18M | 2.46% | 391,099 -128,868 | -25% | -$1.71M |
|
19
AC Immune
ACIU
$205M
| $4.51M | 2.14% | 923,117 -253,684 | -22% | -$1.24M |
|
|
ALBO
20
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $4.09M | 1.94% | 122,500 -76,300 | -38% | -$2.55M |
|
|
21
Iovance Biotherapeutics
IOVA
$807M
| $3.97M | 1.89% | 120,606 -94,394 | -44% | -$3.11M |
|
|
TBIO
22
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $3.84M | 1.83% | 282,100 +192,590 | +215% | +$2.62M |
|
|
CLLS
23
Cellectis
CLLS
$258M
| $3.43M | 1.63% | 185,180 -91,397 | -33% | -$1.69M |
|
|
24
Kura Oncology
KURA
$686M
| $3.29M | 1.56% | 107,367 -577,633 | -84% | -$17.7M |
|
|
ZGNX
25
DELISTED
Zogenix, Inc.
ZGNX
| $3.24M | 1.54% | 180,924 +34,578 | +24% | +$620K |
|